

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

SANDOZ INC.,  
Petitioner,

v.

PHARMACYCLICS LLC,  
Patent Owner.

---

Case IPR2019-00865  
U.S. Patent No. 9,795,604

---

**DECLARATION OF DR. JOHN KORETH, M.B.B.S., D. Phil.**

## TABLE OF CONTENTS

I.	INTRODUCTION .....	9
II.	PROFESSIONAL BACKGROUND AND QUALIFICATIONS .....	9
III.	MATERIALS CONSIDERED .....	13
IV.	BACKGROUND OF GRAFT VERSUS HOST DISEASE .....	14
A.	cGVHD Is a Major and Life-threatening Complication of HCT .....	14
B.	cGVHD Is Distinct From and Treated Differently Than aGVHD.....	16
C.	The Pathogenesis of cGVHD Is Complex and Incompletely Understood .....	18
D.	Treatment of cGVHD Is Difficult, Especially in Steroid- Dependent/Refractory, Steroid-Resistant, or Refractory cGVHD Patients .....	23
E.	Before 2013 There Were Many Treatment Failures and No FDA Approved Drugs for cGVHD .....	28
V.	THE '604 PATENT.....	32
A.	The Specification.....	32
B.	The Claims .....	35
VI.	PERSON OF ORDINARY SKILL IN THE ART .....	38
VII.	CLAIM CONSTRUCTION .....	39
A.	Legal Standards for Claim Construction.....	39
B.	Claims 1 and 55: “method of treating chronic graft versus host disease (GVHD)” and “thereby treating the chronic GVHD in the patient” .....	41
C.	Claims 6-8, 29-31, 44-46, and 51-53: the “wherein” efficacy limitations .....	44

D.	Claim 1: “therapeutically effective amount” .....	46
E.	The clinical efficacy limitations are not inherent to the claimed methods.....	46
VIII.	THE ASSERTED REFERENCES .....	47
A.	The '085 Publication (Ex. 1002).....	47
B.	Shimabukuro-Vornhagen (Ex. 1003).....	51
C.	Herman (Ex. 1004).....	54
D.	Uckun (Ex. 1005).....	55
IX.	LEGAL STANDARDS FOR PATENTABILITY.....	56
A.	Anticipation.....	57
B.	Obviousness.....	58
X.	THE '085 PUBLICATION DOES NOT DESCRIBE THE CLAIMED METHODS OF TREATING CHRONIC GVHD WITH IBRUTINIB (GROUND 1).....	59
A.	The '085 Publication Does Not Anticipate the Challenged Claims.....	59
B.	The '085 Publication Does Not Enable Treating cGVHD With Ibrutinib Without Undue Experimentation (Claims 1, 4, 6-10, 13, 15, 24, 28-31, 35, 39, 43-46, 50-53, and 55).....	60
1.	The Nature of the Invention / Relative Level of Skill .....	61
2.	The State and Unpredictability of the Prior Art.....	62
3.	The Quantity of Experimentation / The Lack of Direction or Guidance / The Absence of Working Examples .....	63
C.	The '085 Publication Does Not Describe the Subject Matter of Claims 4, 13, and 15 and the Claims that Depend From Them (Claims 28-31, 43-46, and 50-53) .....	67

D. The '085 Publication Does Not Disclose the Specific Efficacy Outcomes of Claims 6-8, 29-31, 44-46, and 51-53.....70

XI. A POSA WOULD NOT HAVE BEEN MOTIVATED TO USE IBRUTINIB TO TREAT cGVHD, AND WOULD NOT HAVE REASONABLY EXPECTED SUCCESS IN TREATING, STEROID-DEPENDENT/REFRACTORY, STEROID-RESISTANT, AND REFRACTORY cGVHD .....72

A. Ground 2: The '085 Publication and a POSA's Knowledge Do Not Render Obvious Claims 4, 13, 15, 28-31, 43-46, and 50-53 .....72

B. Ground 3: The Combination of the '085 Publication, Shimabukuro-Vornhagen, and Herman Does Not Render Obvious Claims 4, 13, 15, 28-31, 43-46, and 50-53 .....77

1. None of The Cited References Contain Any *In Vitro*, Preclinical, or Clinical Data for Ibrutinib in cGVHD.....80

2. Shimabukuro-Vornhagen's Disclosures Regarding B-Cell Involvement and Rituximab Do Not Provide a Reason to Focus on Ibrutinib With a Reasonable Expectation of Success .....81

a. The role of B cells in cGVHD pathogenesis was complex and incompletely understood in 2013.....81

b. Rituximab and ibrutinib are very different drugs .....85

c. Covalent BTK inhibitors and drugs targeting both B and T cells raised significant safety concerns in steroid-dependent/refractory, steroid-resistant, or refractory cGVHD patients.....88

d. A POSA would have been skeptical of the rituximab studies referenced in Shimabukuro-Vornhagen.....91

3. Herman's Disclosures Regarding Cytokines Do Not Fill the Gaps in the Asserted References.....95

C. Ground 4: The Combination of the '085 Publication, Shimabukuro-Vornhagen, and Uckun Does Not Render Obvious Claims 4, 13, 15, 28-31, 43-46, and 50-53 .....97

1. Uckun, Like the '085 Publication and Shimabukuro-Vornhagen, Does Not Contain Any *In Vitro*, Preclinical, or Clinical Data for Ibrutinib in cGVHD .....99

2. Uckun Shows that LFM-A13 Alone Demonstrated Limited Efficacy in Preventing aGVHD .....99

3. aGVHD Is Distinct From cGVHD and GVHD Prophylaxis Cannot be Conflated with GVHD Treatment .....101

XII. GROUNDS 2-4 DO NOT PROVIDE MOTIVATION OR A REASONABLE EXPECTATION OF SUCCESS TO ACHIEVE THE METHODS OF CLAIM 1 .....103

XIII. CLAIMS 6-8, 29-31, 44-46, AND 51-53 ARE NOT OBVIOUS OVER ANY OF THE ASSERTED REFERENCES BECAUSE OF THEIR SPECIFIC CLINICAL EFFICACIES .....104

XIV. THE COMBINED ASSERTED REFERENCES DO NOT PROVIDE ANY REASON TO TARGET A DAILY DOSE OF 420 MG/DAY AS CLAIMED IN CLAIMS 24, 28, 35, 39, 43, 50, AND 55.....107

XV. ADDITIONAL OBJECTIVE EVIDENCE DEMONSTRATES THAT THE CLAIMED METHODS ARE NOT OBVIOUS.....110

A. Treatment of cGVHD Is Replete With Failures.....111

B. The Claimed Methods Fulfilled a Long-Felt But Unmet Need .....113

C. The Claimed Methods Achieved Unexpected Results.....118

D. Praise and Industry Acclaim for Imbruvica® .....119

E. There Is a Nexus Between the Claimed Invention and the Objective Evidence.....123

XVI. CONCLUSION.....141

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.